FindTrial
Sign In

Dynamic monitoring of residual tumor lesions based on plasma circulating tumor DNA (ctDNA) for prognosis and treatment evaluation of patients with ovarian cancer undergoing surgical resection

Dynamic monitoring of residual tumor lesions based on plasma circulating tumor DNA (ctDNA) for prognosis and treatment evaluation of patients with ovarian cancer undergoing surgical resection

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300072927
Enrollment
Unknown
Registered
2023-06-28
Start date
2022-11-08
Completion date
Unknown
Last updated
2023-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian cancer

Interventions

Gold Standard:CT
Index test:plasma ctDNA

Sponsors

Affiliated Hospital of Guangdong Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Aged over 18 years old 2. Patients with ovarian cancer confirmed by histology and/or cytology 3. The patient requires surgery 4. Fitness Status Score (ECOG) <=1 point 5. Expected survival more than 3 months

Exclusion criteria

Exclusion criteria: 1. Patients who did not receive surgical treatment or did not meet the criteria for surgical resection after surgical treatment. 2. Patients with other primary cancers. 3. Patients with other gynecological diseases 4. Pregnant or lactating women. 5. Patients with severe mental illness.

Design outcomes

Primary

MeasureTime frame
median recurrence time;—

Secondary

MeasureTime frame
specificity;sensitivity;—

Countries

CHINA

Contacts

Public ContactYing Zhang

Affiliated Hospital of Guangdong Medical University

zhangying5413@126.com+86 135 4200 6885

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026